Using the nanopore-based molecular sensing technology developed by Oxford Nanopore, Mayo Clinic researchers can develop new clinical tests to sequence a patient’s DNA and examine methylation — a biochemical process that regulates gene expression — in real time, according to an Oct. 19 news release.
Typically, examining methylation is a separate process that requires additional time and cost. The ability to do this in real-time will allow clinicians to see a more complete picture of a patient’s cancer genome.
The partnership ultimately “further helps advance patient care,” Bobbi Pritt, MD, the interim chair of Mayo Clinic’s Department of Laboratory Medicine and Pathology, stated in the release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
